MCL1 and hematopoietic and lymphoid cell neoplasm: The highly selective CDK9 inhibitor, AZD4573, induced apoptosis and subsequent cell death in hematologic cancer models in vitro and favored tumor regression in tumor xenografts in vivo, through the indirect inhibition of Mcl-1 [161].